Original Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 7, 2013; 19(21): 3207-3216
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3207
Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases
Luigi Fenoglio, Cristina Serraino, Elisabetta Castagna, Adele Cardellicchio, Fulvio Pomero, Maurizio Grosso, Carlo Senore
Luigi Fenoglio, Cristina Serraino, Elisabetta Castagna, Adele Cardellicchio, Fulvio Pomero, Department of Internal Medicine, Santa Croce Hospital, 12100 Cuneo, Piedmont, Italy
Maurizio Grosso, Department of Diagnostic Radiology, Santa Croce Hospital, 12100 Cuneo, Piedmont, Italy
Carlo Senore, AO Città della Salute e della Scienza, CPO Piemonte, 10123 Turin, Piedmont, Italy
Author contributions: Fenoglio L, Castagna E and Grosso M conceived and designed the study; Serraino C, Castagna E, Pomero F and Senore C acquired, analyzed and interpreted the data; Fenoglio L, Serraino C, Castagna E and Senore C drafted the manuscript; Serraino C, Castagna E and Cardellicchio A wrote the paper; Fenoglio L approved the final published version.
Correspondence to: Dr. Luigi Fenoglio, Department of Internal Medicine, Santa Croce Hospital, Via Michele Coppino 26, 12100 Cuneo, Piedmont, Italy. fenoglio.l@ospedale.cuneo.it
Telephone: +39-171-641308   Fax: +39-171-641306
Received: November 28, 2012
Revised: January 30, 2013
Accepted: March 15, 2013
Published online: June 7, 2013
Processing time: 187 Days and 13.5 Hours
Abstract

AIM: To analyze the epidemiology, clinical characteristics, treatment patterns and outcome in hepatocellular carcinoma (HCC) patients.

METHODS: We analyzed clinical, pathological and therapeutic data from 256 consecutive patients, examined at S. Croce Hospital in Cuneo-Piedmont, with a diagnosis of HCC between 30th June 2000 and 1st July 2010. We analyzed the hospital imaging database and examined all medical records, including the diagnosis code for HCC (155.0 according to the ICD-9M classification system), both for inpatients and outpatients, and discovered 576 relevant clinical records. After the exclusion of reports relating to multiple admissions for the same patient, we identified 282 HCC patients. Moreover, from this HCC series, we excluded 26 patients: 1 patient because of an alternative final diagnosis, 8 patients because of a lack of complete clinical data in the medical record and 17 patients because they were admitted to different health care facilities, leaving 256 HCC patients. To highlight possible changes in HCC patterns over the ten-year period, we split the population into two five-year groups, according to the diagnosis period: 30th June 2000-30th June 2005 and 1st July 2005-1st July 2010. Patients underwent a 6-mo follow up.

RESULTS: Two hundred and fifty-six HCC patients were included (male/female 182/74; mean age 70 years), 133 in the first period and 123 in the second. Hepatitis C virus (HCV) infection was the most common HCC risk factor (54.1% in the first period, 50.4% in the second; P = 0.63); in the first period, 21.8% of patients were alcoholics and 15.5% were alcoholics in the second period (P > 0.05); the non-viral/non-alcoholic etiology rate was 3.7% in the first period and 20.3% in the second period (P < 0.001). Child class A patients increased significantly in the second period (P < 0.001). Adjusting for age, gender and etiology, there was a significant increase in HCC surveillance during the second period (P = 0.01). Differences between the two periods were seen in tumor parameters: there was an increase in the number of unifocal HCC patients, from 53 to 69 (P = 0.01), as well as an increase in the number of cases where the HCC was < 3 cm [from 22 to 37 (P = 0.01)]. The combined incidence of stage Barcelona Clinic Liver Cancer 0 (very-early) and A (early) HCC was 46 (34.6%) between 2000-2005, increasing to 62 (50.4%) between 2005-2010 (P = 0.01). Of the patients, 62.4% underwent specific treatment in the first group, which increased to 90.2% in the second group (P < 0.001). Diagnosis period (P < 0.01), Barcelona-Clinic Liver Cancer stage (P < 0.01) and treatment per se (P < 0.05) were predictors of better prognosis; surveillance was not related to survival (P = 0.20).

CONCLUSION: This study showed that, between 2000-2005 and 2005-2010, the number of HCV-related HCC decreased, non-viral/non alcoholic etiologies increased and of surveillance programs were more frequently applied.

Keywords: Hepatocellular carcinoma; Epidemiology; Clinical characteristics; Surveillance; Survival

Core tip: Hepatocellular carcinoma (HCC) is the 5th most common cancer and the 3rd leading cause of cancer mortality worldwide. In recent decades, the incidence of HCC has risen in Europe and the United States. This study showed that, between 2000-2005 and 2005-2010, the number of hepatitis C virus-related HCC decreased, non-viral/non alcoholic etiologies increased and of surveillance programs were more frequently applied.